Lv51
930 积分 2024-12-12 加入
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
7天前
已完结
First-line Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
28天前
已完结
First-line Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
29天前
已关闭
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine–oxaliplatin versus short-course radiotherapy followed by capecitabine–oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial
2个月前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
2个月前
已完结
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
3个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
3个月前
已完结
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer
3个月前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
3个月前
已完结
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
4个月前
已完结
皖公网安备34019202002308
